Home > Cardiology > AHA 2021 > Heart Failure > DREAM-HF: MPC therapy for HFrEF did not meet primary endpoint

DREAM-HF: MPC therapy for HFrEF did not meet primary endpoint

Presented By
Dr Emerson Perin, Texas Heart Institute, US
Conference
AHA 2021
Trial
Phase 3, DREAM-HF
Transendocardial delivery of mesenchymal precursor cells (MPCs) did not reduce cumulative recurrent non-fatal decompensated heart failure (HF) events in HF patients with a reduced ejection fraction (HFrEF). However, a single dose of MCPs was associated with lower rates of non-fatal myocardial infarction, non-fatal stroke, and cardiac death. These effects were more pronounced in patients with baseline inflammation. Dr Emerson Perin (Texas Heart Institute, TX, USA) argued that MPCs may decrease cardiac inflammation, reduce heart muscle death, induce a microvascular network in heart muscle, and reverse endothelial dysfunction [1]. In a recent phase 2 trial, MPCs showed promising results in reducing HF-associated events in patients with high-risk, persistent HFrEF [2]. The multicentre, double-blind, sham-controlled, phase 3 DREAM-HF trial (NCT02032004) randomised 537 p...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on